ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, inclusive, with ADHD. Supernus expects to enroll 50 subjects in the study at 5 sites across the United States. The primary objective is to measure safety and tolerability, with a secondary measure of efficacy in reducing symptoms of ADHD. SPN812 has previously been marketed outside the United States with a good tolerability and safety profile.
